Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business

Related Content

J&J Options In Face Of Merck’s Schering Bid Include OTC Deal
Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
Pfizer’s Wyeth Buy Rebuilds OTC Switch Potential
Pfizer/Wyeth Merger Would Offer Diversification, Switch Outlet
Diversification Versus Focus Dilemma Spotlights OTC Business Value
CSA fine for J&J
J&J’s Consumer Sales Buoyed By Listerine In Third Quarter
Chattem/J&J deal closes
J&J closes Pfizer deal
EC extends J&J/Pfizer look





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts